Peak6 LLC Invests $707,000 in Cellebrite DI Ltd. (NASDAQ:CLBT)

Peak6 LLC purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,099 shares of the company’s stock, valued at approximately $707,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. True Wind Capital Management L.P. increased its position in shares of Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. FMR LLC raised its position in Cellebrite DI by 89.1% in the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after purchasing an additional 5,004,587 shares during the period. Pertento Partners LLP lifted its position in Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after acquiring an additional 626,373 shares in the last quarter. Pembroke Management LTD boosted its holdings in Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after acquiring an additional 84,087 shares during the period. Finally, Crescent Park Management L.P. grew its position in Cellebrite DI by 8.3% in the fourth quarter. Crescent Park Management L.P. now owns 1,862,482 shares of the company’s stock valued at $41,030,000 after acquiring an additional 142,534 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CLBT shares. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Price Performance

Shares of CLBT opened at $18.90 on Monday. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The business’s fifty day moving average price is $18.99 and its 200 day moving average price is $20.10. The stock has a market capitalization of $4.53 billion, a PE ratio of -13.60, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.